Human Brain Mapping, 36(11), 44974511
CJC-1295 activates the pituitary gland to increase growth hormone release in a natural pulse-pattern, helping: Build and maintain lean muscle Burn fat for fuel Improve protein synthesis & cell repair Enhance sleep quality Support youthful skin, hair, and bones Unlike synthetic HGH injections, CJC-1295 does not replace hormones it boosts your bodys own production for safer, steady results
This comparison clearly highlights an adaptation of the cells toward a more sensitized state upon initial NFT exposure, thus enabling a pharmacological elevation of glutathione levels by even lower doses of repeated NFT treatments
2.2.2 T cells T follicular helper (T FH ) cells display distinct lipid metabolic profiles, characterized by the localization of phosphatidylethanolamine predominantly on the outer plasma membrane

CJC-1295 Compounded Equivalent: Pricing, Access, and What to Know in 2026 At a glance Generic name / Modified GRF 1-29 (tetrasubstituted GRF 1-29) FDA approval status / No FDA-approved product exists Supply route / 503A and 503B compounding pharmacies only Typical monthly cost / $150 to $350 depending on dose and pharmacy Insurance coverage / Not covered by commercial or government plans Prescription required / Yes, from a licensed prescriber Common pairing / Ipamorelin (combined vial widely available) Typical dosing / 100 to 300 mcg subcutaneous injection, 1 to 3 times daily FDA regulatory note / FDA has placed CJC-1295 on the Category 2 bulk substance list for ongoing review Key safety signal / Injection-site reactions, flushing, transient hypotension reported in clinical studies Why CJC-1295 Exists Only as a Compounded Product No pharmaceutical manufacturer has submitted a New Drug Application for CJC-1295 to the FDA, so it has never received approval as a finished dosage form